[go: up one dir, main page]

DE60329123D1 - Benzoädüazepinderivate für die behandlung von neurologischen krankheiten - Google Patents

Benzoädüazepinderivate für die behandlung von neurologischen krankheiten

Info

Publication number
DE60329123D1
DE60329123D1 DE60329123T DE60329123T DE60329123D1 DE 60329123 D1 DE60329123 D1 DE 60329123D1 DE 60329123 T DE60329123 T DE 60329123T DE 60329123 T DE60329123 T DE 60329123T DE 60329123 D1 DE60329123 D1 DE 60329123D1
Authority
DE
Germany
Prior art keywords
benzoedetazepine
derivatives
treatment
neurological diseases
neurological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60329123T
Other languages
English (en)
Inventor
Mark James Bamford
David Kenneth Dean
Sanjeet Singh Sehmi
David Matthew Wilson
Jason Witherington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0229820A external-priority patent/GB0229820D0/en
Priority claimed from GB0312607A external-priority patent/GB0312607D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60329123D1 publication Critical patent/DE60329123D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60329123T 2002-12-20 2003-12-18 Benzoädüazepinderivate für die behandlung von neurologischen krankheiten Expired - Lifetime DE60329123D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0229820A GB0229820D0 (en) 2002-12-20 2002-12-20 Novel compounds
GB0312607A GB0312607D0 (en) 2003-06-02 2003-06-02 Novel compounds
PCT/EP2003/014556 WO2004056369A1 (en) 2002-12-20 2003-12-18 Benzo ‘ d!azepine derivatives for the treatment of neurological disorders

Publications (1)

Publication Number Publication Date
DE60329123D1 true DE60329123D1 (de) 2009-10-15

Family

ID=32683982

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60329123T Expired - Lifetime DE60329123D1 (de) 2002-12-20 2003-12-18 Benzoädüazepinderivate für die behandlung von neurologischen krankheiten

Country Status (28)

Country Link
US (4) US7696193B2 (de)
EP (3) EP1572215B1 (de)
JP (2) JP4584831B2 (de)
KR (2) KR100765027B1 (de)
AR (1) AR042542A1 (de)
AT (1) ATE441417T1 (de)
AU (1) AU2003294909B2 (de)
BR (1) BR0317483A (de)
CA (1) CA2509413C (de)
CY (1) CY1109558T1 (de)
DE (1) DE60329123D1 (de)
DK (1) DK1572215T3 (de)
EG (1) EG25204A (de)
ES (3) ES2333008T3 (de)
HK (1) HK1085647A1 (de)
IL (2) IL169091A (de)
IS (1) IS2907B (de)
MA (1) MA27582A1 (de)
MX (1) MXPA05006567A (de)
MY (1) MY138478A (de)
NO (2) NO331068B1 (de)
NZ (1) NZ540148A (de)
PL (2) PL220722B1 (de)
PT (1) PT1572215E (de)
RU (2) RU2388752C2 (de)
SI (1) SI1572215T1 (de)
TW (1) TWI323256B (de)
WO (1) WO2004056369A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2333008T3 (es) * 2002-12-20 2010-02-16 Glaxo Group Limited Derivados de benzo(d)azepina para el tratamiento de trastornos neurologicos.
DE602004017206D1 (de) 2003-10-23 2008-11-27 Hoffmann La Roche Benzazepin-derivate als mao-b-hemmer
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0405628D0 (en) * 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds
GB0408083D0 (en) * 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
TW200611701A (en) * 2004-06-18 2006-04-16 Glaxo Group Ltd Novel compounds
GB0418267D0 (en) * 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds
EP1836171A1 (de) 2005-01-07 2007-09-26 Glaxo Group Limited 6-(2,3,4,5-tetrahydro-1h-benzo[d]azepin-7-yloxy)nikotinsäureamidderivate als radioaktiv markierte liganden
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
WO2007045989A1 (en) * 2005-10-20 2007-04-26 Pfizer Limited Pyridyl derivatives useful as h3 ligands
CN101296902A (zh) 2005-10-27 2008-10-29 Ucb医药有限公司 包含内酰胺或内酰胺衍生部分的化合物、制备它们的方法和它们的用途
BRPI0618692A2 (pt) * 2005-11-18 2011-09-06 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os contém, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos, tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
KR101372941B1 (ko) * 2006-05-30 2014-03-14 얀센 파마슈티카 엔.브이. 히스타민 ｈ３ 수용체 조절제로서의 치환된 피리딜 아미드 화합물
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
NZ611323A (en) 2006-06-23 2014-10-31 Abbvie Bahamas Ltd Cyclopropyl amine derivatives as histamin h3 receptor modulators
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
GB2441014A (en) * 2006-09-14 2008-02-20 Glaxo Group Ltd Polymorphic form of 6-(3-cyclobuty1-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-methyl-nicotinamide hydrochloride for use in therapy
CL2008000597A1 (es) * 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 6-(3-ciclobutil-2,3,4,5-tetrahidro-1h-benzo[d]azepin-7-il oxi)-n-metil nicotinamida, un estabilizante y un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
CL2008000596A1 (es) * 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
DK2465541T3 (en) 2007-05-22 2018-09-17 Wyeth Llc improved methods for producing hydrazides
AU2008294708B2 (en) * 2007-09-06 2012-03-15 Glaxo Group Limited Piperazine derivative having affinity for the histamine H3 receptor
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011051423A1 (en) 2009-11-02 2011-05-05 Glaxo Group Limited Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy
WO2011083316A1 (en) * 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Benzazepine derivatives for the treatment of central nervous system disorders
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
EA023260B1 (ru) * 2011-02-23 2016-05-31 Сувен Лайф Сайенсиз Лимитед Новые соединения в качестве лигандов гистаминовых h-рецепторов
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
EP2686310B1 (de) 2011-03-14 2017-12-13 Boehringer Ingelheim International GmbH Benzodioxanhemmer der leukotrienproduktion
EP2734516B1 (de) 2011-07-19 2015-06-17 Boehringer Ingelheim International GmbH Arylpyrazolether als inhibitoren der leukotrien-a4 hydrolase
CA2863022A1 (en) * 2012-01-16 2013-07-25 Glaxosmithkline Intellectual Property Development Limited Therapeutic uses
CN104114538B (zh) * 2012-01-16 2016-04-13 葛兰素史克知识产权发展有限公司 治疗用途
NZ628587A (en) 2012-03-06 2016-07-29 Boehringer Ingelheim Int Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (de) 2012-04-06 2013-10-09 Sanofi Verwendung eines H3-Rezeptorantagonisten zur Behandlung von Morbus Alzheimer
TW201416354A (zh) 2012-07-17 2014-05-01 Boehringer Ingelheim Int 白三烯生成抑制劑
US9303018B2 (en) 2013-07-15 2016-04-05 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
EP3022194B1 (de) 2013-07-15 2017-05-17 Boehringer Ingelheim International GmbH Hemmer der leukotrienproduktion
US10526323B2 (en) 2015-01-30 2020-01-07 Vanderbilt University Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP4251148A1 (de) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamin-h3-rezeptorantagonisten/inversagonisten zur behandlung von autismusspektrumsstörungen
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3393192A (en) 1965-04-26 1968-07-16 Schering Corp Novel benzazepines
CA974989A (en) 1968-03-11 1975-09-23 Wallace And Tiernan Inc. Process for preparing 1,2,4,5-tetrahydro-3h,3-benzazepines and products obtained thereby
US4233217A (en) 1968-03-11 1980-11-11 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines
FR2171879A1 (en) 1972-02-14 1973-09-28 Pennwalt Corp 1,2,4,5-tetrahydro-3h-3-benzazepines - analgesics narcotic antagonists, antihistamines etc
US4210749A (en) 1974-11-12 1980-07-01 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
US4206210A (en) 1977-01-19 1980-06-03 Smithkline Corporation Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
US4843081A (en) 1984-09-04 1989-06-27 Rorer Pharmaceutical Corporation Aryl and heteroaryl substituted cycloalkyl compounds
US5175157A (en) 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3717561A1 (de) 1987-05-25 1988-12-08 Thomae Gmbh Dr K Indol-, isochinolin- und benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS6394239A (ja) 1986-10-08 1988-04-25 Konica Corp 色素画像の安定性を改良したハロゲン化銀写真感光材料
ZA882080B (en) * 1987-03-27 1989-04-26 Schering Corp Substituted benzazepines,their preparation and pharmaceutical compositions containing them
DK325188D0 (da) 1988-06-15 1988-06-15 Novo Industri As Hidtil ukendte benzazepinderivater
FR2642756B1 (fr) 1989-02-07 1994-03-04 Sanofi Derives cycloaminoalkoxyphenyle, leur procede de preparation ainsi que les compositions pharmaceutiques ou veterinaires en contenant
US4959374A (en) 1989-07-06 1990-09-25 Beecham Group P.L.C. Novel compounds
WO1991019698A1 (en) 1990-06-15 1991-12-26 Schering Corporation 8-lower alkyl-5-cycloalkyl or 5-cycloalkenyl substitued benzazepines and pharmaceutical compositions containing them
TW197435B (de) 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
KR940701258A (ko) 1991-06-21 1994-05-28 피터 죤 기딩즈 문맥압 항진증 및 편두통의 치료를 위한 테트라하이드로벤즈아제핀 유도체의 용도
GB9116824D0 (en) 1991-08-05 1991-09-18 Smithkline Beecham Corp Chemical compounds
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
JPH05194406A (ja) 1991-11-12 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 新規アミド化合物
US5241065A (en) 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
JPH05239024A (ja) 1992-02-28 1993-09-17 Takeda Chem Ind Ltd 縮合複素環カルボン酸誘導体、その製造法、中間体および剤
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
SE9300657D0 (sv) 1993-02-26 1993-02-26 Astra Ab New compounds
US5387685A (en) 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents
AU1090795A (en) 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
CA2176808A1 (en) 1993-11-18 1995-05-26 Scott Hultgren Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections
DE4429079A1 (de) 1994-08-17 1996-02-22 Thomae Gmbh Dr K Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19530996A1 (de) 1995-08-23 1997-02-27 Boehringer Mannheim Gmbh Cyclische Guanidine, Verfahren zu ihrer Herstellung und Arzneimittel
EP0920417A4 (de) 1996-08-15 1999-12-29 Smithkline Beecham Corp Il-8 rezeptor antagonisten
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU5495398A (en) 1997-01-17 1998-08-07 Takeda Chemical Industries Ltd. Idebenone containing combination agent for treating alzheimer's disease
GB9724372D0 (en) 1997-11-18 1998-01-14 Smithkline Beecham Plc Novel compounds
EP1043311A4 (de) 1997-11-20 2001-01-24 Teijin Ltd Biphenylamidin-derivate
BR9908545A (pt) 1998-02-02 2001-10-02 Lg Chemical Ltd Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica
EP0937723A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
WO1999054310A2 (de) 1998-04-20 1999-10-28 Basf Aktiengesellschaft Neue substituierte amide, deren herstellung und anwendung
AU3523599A (en) 1998-04-29 1999-11-16 Smithkline Beecham Plc Quinolones used as mrs inhibitors and bactericides
EP0982300A3 (de) 1998-07-29 2000-03-08 Societe Civile Bioprojet Alkylamine ohne Imidazolring als Histamin-H3-antagonisten und deren therapeutische Anwendung
GB9816982D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
CO5140073A1 (es) 1998-10-08 2002-03-22 Smithkline Beecham Plc Derivados de 2,3,4,5-tetrahidro-1h-3-benzapina
WO2000023437A1 (fr) 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Composes azotes hererocycliques condenses; procede de fabrication et agents les renfermant
WO2000038618A2 (en) 1998-12-24 2000-07-06 Du Pont Pharmaceuticals Company SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
GB9914255D0 (en) 1999-06-18 1999-08-18 Lilly Forschung Gmbh Pharmaceutical compounds
EP1237547A2 (de) 1999-07-09 2002-09-11 Isis Innovation Limited Verbindungen zur krankheitshemmung und zur bereitung von zellen zur transplantation
DE60006618T2 (de) 1999-08-06 2004-09-23 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
AU1569501A (en) 1999-11-09 2001-06-06 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis
WO2001055118A1 (fr) 2000-01-26 2001-08-02 Ono Pharmaceutical Co., Ltd. Derives heterocycliques condenses au benzene et medicaments contenant ceux-ci comme ingredients actifs
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
ES2248242T3 (es) 2000-04-21 2006-03-16 Pfizer Products Inc. Ligandos de receptores tiroideos.
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
JP2002371059A (ja) * 2000-05-16 2002-12-26 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
CA2414976A1 (en) 2000-07-04 2002-01-10 Takeda Chemical Industries, Ltd. Gpr14 antagonistic agent
WO2002014513A1 (en) 2000-08-10 2002-02-21 Takeda Chemical Industries, Ltd. Use of polypeptide
WO2002015934A1 (fr) 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents prophylactiques et remedes contre des maladies du systeme nerveux central
ATE382617T1 (de) 2000-11-14 2008-01-15 Smithkline Beecham Plc Tetrahydrobenzazepin-derivate zur verwendung als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
UA77165C2 (en) 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
FR2819512B1 (fr) 2001-01-18 2003-02-21 Servier Lab Nouveaux composes cyclo[d] azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CZ303750B6 (cs) 2001-02-02 2013-04-17 Bristol-Myers Squibb Company Prostredky obsahující substituované deriváty azaindoloxoacetylpiperazinu a jejich antivirová aktivita
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
BR0309556A (pt) 2002-04-26 2005-02-09 Pfizer Prod Inc Inibidores de metaloproteinase pirimidina-2,4,6-triona
ATE308544T1 (de) 2002-04-26 2005-11-15 Pfizer Prod Inc N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
JP2006500376A (ja) 2002-08-20 2006-01-05 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニストとしての置換アゼピン、製造および治療上の使用
MXPA05003093A (es) 2002-09-19 2005-07-13 Lilly Co Eli Diaril eteres como antagonistas de receptor opiode.
GB0224083D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
ES2333008T3 (es) 2002-12-20 2010-02-16 Glaxo Group Limited Derivados de benzo(d)azepina para el tratamiento de trastornos neurologicos.
AU2003292625B2 (en) 2002-12-26 2008-07-24 Eisai R & D Management Co., Ltd. Selective estrogen receptor modulators
WO2004069244A1 (en) 2003-02-07 2004-08-19 Warner-Lambert Company Llc Oxazolidinone derivatives n-substituted by a bicyclic ring, for use as antibacterial agents
CA2536659A1 (en) 2003-08-08 2005-02-17 Glaxo Group Limited Process
DE602004017206D1 (de) 2003-10-23 2008-11-27 Hoffmann La Roche Benzazepin-derivate als mao-b-hemmer
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
CA2550053C (en) 2003-12-18 2013-01-22 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor
GB0405628D0 (en) 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds
GB0408083D0 (en) 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
TW200611701A (en) 2004-06-18 2006-04-16 Glaxo Group Ltd Novel compounds
GB0418267D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
US20090105226A1 (en) 2009-04-23
RU2005122932A (ru) 2006-04-10
ES2401216T3 (es) 2013-04-17
JP4584831B2 (ja) 2010-11-24
AR042542A1 (es) 2005-06-22
KR100897642B1 (ko) 2009-05-14
IL169091A0 (en) 2007-07-04
PL397229A1 (pl) 2012-02-27
BR0317483A (pt) 2005-11-16
HK1085647A1 (en) 2006-09-01
CA2509413A1 (en) 2004-07-08
DK1572215T3 (da) 2010-01-11
KR20050088195A (ko) 2005-09-02
AU2003294909A1 (en) 2004-07-14
NO20110408L (no) 2005-09-15
MA27582A1 (fr) 2005-10-03
RU2388752C2 (ru) 2010-05-10
KR20070089762A (ko) 2007-08-31
TWI323256B (en) 2010-04-11
NO20053384D0 (no) 2005-07-12
AU2003294909B2 (en) 2007-05-17
RU2423353C1 (ru) 2011-07-10
PL220722B1 (pl) 2015-12-31
PT1572215E (pt) 2009-12-09
EP1572215B1 (de) 2009-09-02
EP1572215A1 (de) 2005-09-14
IL169091A (en) 2011-11-30
US7704994B2 (en) 2010-04-27
ES2401319T3 (es) 2013-04-18
EG25204A (en) 2011-11-14
NO331068B1 (no) 2011-09-26
SI1572215T1 (sl) 2010-01-29
US7799773B2 (en) 2010-09-21
IS7941A (is) 2005-07-18
US7696193B2 (en) 2010-04-13
EP2133340A1 (de) 2009-12-16
ATE441417T1 (de) 2009-09-15
JP2006512412A (ja) 2006-04-13
JP2010248239A (ja) 2010-11-04
KR100765027B1 (ko) 2007-10-09
MXPA05006567A (es) 2005-08-16
US8207331B2 (en) 2012-06-26
TW200500344A (en) 2005-01-01
JP5315299B2 (ja) 2013-10-16
IL202827A (en) 2011-08-31
US20060040918A1 (en) 2006-02-23
PL377315A1 (pl) 2006-01-23
NO20053384L (no) 2005-09-15
ES2333008T3 (es) 2010-02-16
IS2907B (is) 2014-11-15
EP2133340B1 (de) 2013-01-16
EP2186516B1 (de) 2013-01-16
MY138478A (en) 2009-06-30
CY1109558T1 (el) 2014-08-13
CA2509413C (en) 2012-05-01
US20100145040A1 (en) 2010-06-10
RU2009138602A (ru) 2011-04-27
NZ540148A (en) 2007-11-30
WO2004056369A1 (en) 2004-07-08
NO332218B1 (no) 2012-07-30
US20070299056A1 (en) 2007-12-27
EP2186516A1 (de) 2010-05-19

Similar Documents

Publication Publication Date Title
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE60233414D1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
DE60226702D1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE402165T1 (de) Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
DE602005013116D1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
ATE333872T1 (de) Zusammensetzng auf diclofenac-basis für die topische behandlung von erkrankungen des oropharynx
ATE272619T1 (de) Anilin-disulfid-derivate zur behandlung allergischer erkrankungen
DE60218529D1 (de) Isochroman verbindungen für die behandlung von cns-krankheiten
ATE391507T1 (de) S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition